risedronic acid has been researched along with Secondary Hyperparathyroidism in 2 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with menatetrenone, risedronate or regular sunlight exposure are safe and effective in increasing bone mass and reducing the risk of hip fracture in patients with AD." | 2.46 | [Dementia and fracture]. ( Sato, Y, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sato, Y | 1 |
| Torregrosa, JV | 1 |
| Durán, CE | 1 |
| Barros, X | 1 |
| Blasco, M | 1 |
| Arias, M | 1 |
| Cases, A | 1 |
| Campistol, JM | 1 |
1 review available for risedronic acid and Secondary Hyperparathyroidism
| Article | Year |
|---|---|
[Dementia and fracture].
Topics: Accidental Falls; Bone Density; Dementia; Etidronic Acid; Hip Fractures; Humans; Hyperparathyroidism | 2010 |
1 trial available for risedronic acid and Secondary Hyperparathyroidism
| Article | Year |
|---|---|
Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.
Topics: Aged; Alendronate; Alkaline Phosphatase; Arterioles; Calciphylaxis; Calcium; Comorbidity; Diphosphon | 2012 |